MedPath

Physical Activity, Knee Joint Loading and Joint Health

Recruiting
Conditions
Post-traumatic Osteoarthritis
Anterior Cruciate Ligament Injuries
Anterior Cruciate Ligament Reconstruction
Anterior Cruciate Ligament Rupture
Anterior Cruciate Ligament Tear
Registration Number
NCT05306054
Lead Sponsor
University of Bath
Brief Summary

The purpose of this study is to investigate the association between time spent in moderate to vigorous physical activity and markers of cartilage metabolism in the years following anterior cruciate ligament reconstruction.

Detailed Description

Participants attend the laboratory on two or three occasions and wear accelerometers for the 10 days in between the first and second laboratory session. The first laboratory session involves urine sample collection, the completion of questionnaires, blood sample collection, acquisition of cross-sectional images of the thigh and calf, and a whole-body composition scan. The researchers will use the accelerometers at the wrist to measure time spent in moderate to vigorous physical activity, and the accelerometers at the ankle as an analogue for knee joint loading. The second laboratory session will consist of a 30-minute run on an instrumented treadmill (measures force of each step taken) whilst wearing non-invasive reflective markers, electromyography devices, and an accelerometer at the ankle. Participants are also invited to undergo optional repeated blood sampling to measure levels of markers of cartilage production and breakdown during rest and in response to a 30-minute run. If participants volunteer for the optional repeated blood sampling, they will be asked to attend a third laboratory session where blood samples will be taken at 24 hours after the run in the second laboratory session.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
80
Inclusion Criteria
  1. 18-39 years old (i.e., ≥18 and <40 years old)
  2. Had an anterior cruciate ligament injury and reconstruction 1-7 years ago (i.e., ≥1 and ≤7 years ago)
  3. Can have sustained damage to meniscus or cartilage, or sustained bone bruising when injured anterior cruciate ligament
  4. Can participate regardless of the type of reconstruction surgery and if undergone meniscectomy
  5. Completed anterior cruciate ligament reconstruction rehabilitation and either a surgeon, doctor or physiotherapist has provided clearance to participate in physical activity
  6. Be able to attend the University of Bath within 2 hours of waking
Exclusion Criteria
  1. Had another significant knee injury either before, at the same time, or after the anterior cruciate ligament injury (e.g., if they injured another ligament in their knee or had a fracture or dislocation)
  2. Injured the anterior cruciate ligament in both knees (bilateral ACL injury)
  3. Have/are experiencing a musculoskeletal, cardiovascular, respiratory, immune, metabolic or neurological disease or disorder
  4. Under 18 or over 39 (i.e., ≥40) years of age
  5. Body Mass Index ≥40 kg/m²
  6. Pregnancy
  7. Positive responses to the Physical Activity Readiness Questionnaire (aside from any involved knee joint issues)

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Ratio of urine concentration of c-telopeptide of type II collagen to serum concentration of c-propeptide of type II procollagenDay 1

Urine concentration of c-telopeptide of type II collagen (uCTX-II) is a marker of cartilage degradation. Serum concentration of c-propeptide of type II procollagen (sCP-II) is a marker of cartilage synthesis. The ratio between these two biomarkers as an indicator of knee joint health has previously been validated.

Secondary Outcome Measures
NameTimeMethod
Step countDay 3-10

Step count will be measured using GENEActiv accelerometers.

Subcutaneous adipose tissue areaDay 1

We are using peripheral quantitative computerised tomography (pQCT) to measure subcutaneous adipose tissue area. pQCT has previously been validated to measure subcutaneous adipose tissue area.

Muscle cross-sectional areaDay 1

We are using peripheral quantitative computerised tomography (pQCT) to measure muscle cross-sectional area. pQCT has previously been validated to measure muscle cross-sectional area.

Lean mass indexDay 1

We are using dual-energy x-ray absorptiometry (DEXA) to measure lean mass index. DEXA has previously been validated to measure lean mass index.

Tampa Scale of Kinesiophobia - 11 scoreDay 1

The Tampa Scale of Kinesiophobia - 11 (TSK-11) will be used to measure fear of reinjury/movement. It has been validated in patients with musculoskeletal pain and in knee injury populations.

English Knee Self-Efficacy Scale scoreDay 1

The English Knee Self-Efficacy Scale (KSES-E) measures knee specific confidence during everyday tasks and physical activity. The KSES-E has been validated in knee injury populations.

Serum concentration of hyaluronic acidDay 11 and 12

Serum concentration of hyaluronic acid (HA) will be measured as marker of proteoglycan breakdown.

Urine concentration of c-telopeptide of type II collagenDay 1

Urine concentration of c-telopeptide of type II collagen (uCTX-II) is a marker of cartilage degradation.

Time spent in moderate to vigorous physical activityDay 3-10

Time spent in moderate to vigorous physical activity will be measured using GENEActiv accelerometers worn on the wrist. The devices have previously been validated to quantify physical activity domains.

Knee joint reaction forceDay 11

Knee joint reaction force will be measured using musculoskeletal modelling in OpenSim. We will use 3D motion capture to measure joint kinematics, an instrumented treadmill to measure ground reaction forces, and electromyography devices to measure muscle activation.

Muscle densityDay 1

We are using peripheral quantitative computerised tomography (pQCT) to measure muscle density. pQCT has previously been validated to measure muscle density.

Cumulative knee joint reaction forceDays 3-11

We are synchronising data collected by the GENEActiv tri-axial accelerometer with knee joint reaction force during walking and running. We then apply the relationship between these two variables (ascertained during the lab session) to the data collected during the 10 days of wear in free living to provide an estimation of cumulative knee joint reaction force.

Knee Injury and Osteoarthritis Outcome ScoreDay 1

The Knee Injury and Osteoarthritis Outcome Score (KOOS) will be used to measure subjective knee joint health. It asks participants to report their symptoms (e.g., pain, stiffness) and function. The KOOS has been validated in a number of populations including those after knee injury.

Time spent in lower body resistance training per weekDay 1

Time spent in lower body resistance training per week will be used to measure subjective time spent in lower body resistance training such as weights or body weight exercise.

Serum concentration of c-propeptide of type II procollagenDay 1

Serum concentration of c-propeptide of type II procollagen (sCP-II) is a marker of cartilage synthesis.

Intra-muscular fat contentDay 1

We are using peripheral quantitative computerised tomography (pQCT) to measure intra-muscular fat content. pQCT has previously been validated to measure intra-muscular fat content.

Modified Godin Leisure Time Exercise Questionnaire scoreDay 1

The Modified Godin Leisure Time Exercise Questionnaire (GLTEQ) measures subjective physical activity over a typical seven day period.

Serum concentration of chondroitin sulphate 846 epitopeDay 11 and 12

Serum concentration of chondroitin sulphate 846 epitope (sCS846) will be measured as marker of aggrecan synthesis.

Fat mass indexDay 1

We are using dual-energy x-ray absorptiometry (DEXA) to measure fat mass index. DEXA has previously been validated to measure fat mass index.

Trial Locations

Locations (1)

University of Bath

🇬🇧

Bath, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath